University of Washington, Seattle, WA, USA.
University of Colorado, Denver, CO, USA.
Lancet Respir Med. 2014 Apr;2(4):277-84. doi: 10.1016/S2213-2600(14)70011-6. Epub 2014 Feb 18.
Present guidelines for the diagnosis of idiopathic pulmonary fibrosis require histological confirmation of surgical lung biopsy samples when high-resolution CT images are not definitive for usual interstitial pneumonia. We aimed to assess the predictive value of high-resolution CT in a cohort of patients with suspected idiopathic pulmonary fibrosis from a previous randomised trial.
ARTEMIS-IPF was a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial of ambrisentan for adults aged 40-80 years with well-defined idiopathic pulmonary fibrosis and 5% or less honeycombing on high-resolution CT. In December, 2010, an interim analysis showed lack of efficacy and the trial was stopped. In the present follow-on analysis, we assessed patients who were screened for ARTEMIS-IPF who underwent high-resolution CT as part of screening and surgical lung biopsy as part of standard clinical care. A radiologist and a pathologist from a central panel independently assessed anonymised CT scans and biopsy samples. We calculated the positive and negative predictive value of high-resolution CT (classified as usual interstitial pneumonia, possible usual interstitial pneumonia, and inconsistent with usual interstitial pneumonia) for confirmation of histological patterns of usual interstitial pneumonia. This study is registered with ClinicalTrials.gov, number NCT00768300.
315 (29%) of 1087 consecutively screened patients in ARTEMIS-IPF had both high-resolution CT and surgical lung biopsy samples. 108 of 111 patients who met high-resolution CT criteria for usual interstitial pneumonia had histologically confirmed usual interstitial pneumonia (positive predictive value 97·3%, 95% CI 92·3-99·4), as did 79 of 84 patients who met high-resolution CT criteria for possible usual interstitial pneumonia (94·0%, 86·7-98·0). 22 of 120 patients had an inconsistent high-resolution CT pattern for usual interstitial pneumonia that was histologically confirmed as not or possible usual interstitial pneumonia (negative predictive value 18·3%, 95% CI 11·9-26·4).
In the appropriate clinical setting, for patients with possible usual interstitial pneumonia pattern on high resolution CT, surgical lung biopsy sampling might not be necessary to reach a diagnosis of idiopathic pulmonary fibrosis if high-resolution CT scans are assessed by experts at regional sites familiar with patterns of usual interstitial pneumonia and management of idiopathic interstitial pneumonia.
Gilead Sciences.
目前,对于高分辨率 CT 图像不能明确诊断为寻常型间质性肺炎的特发性肺纤维化患者,需要通过手术肺活检来确认病理学诊断。我们旨在评估高分辨率 CT 在一项先前的随机试验中疑似特发性肺纤维化患者队列中的预测价值。
ARTEMIS-IPF 是一项安立生坦治疗年龄在 40-80 岁、具有明确特发性肺纤维化且高分辨率 CT 显示 5%以下蜂窝肺的患者的随机、双盲、安慰剂对照、多中心、3 期临床试验。2010 年 12 月,中期分析显示该药物无效,试验因此停止。在本次后续分析中,我们评估了接受高分辨率 CT 筛查且作为标准临床护理一部分进行了手术肺活检的 ARTEMIS-IPF 筛查患者。来自中央小组的放射科医生和病理学家对匿名 CT 扫描和活检样本进行了独立评估。我们计算了高分辨率 CT(分为寻常型间质性肺炎、可能的寻常型间质性肺炎和与寻常型间质性肺炎不一致)对确认寻常型间质性肺炎组织学模式的阳性和阴性预测值。本研究在 ClinicalTrials.gov 注册,编号为 NCT00768300。
在 ARTEMIS-IPF 中,连续筛查的 1087 例患者中有 315 例(29%)同时进行了高分辨率 CT 和手术肺活检。111 例符合高分辨率 CT 寻常型间质性肺炎标准的患者中,有 108 例经组织学证实为寻常型间质性肺炎(阳性预测值 97.3%,95%CI 92.3-99.4),84 例符合高分辨率 CT 可能寻常型间质性肺炎标准的患者中有 79 例(94.0%,86.7-98.0)。120 例患者的高分辨率 CT 表现不一致,经组织学证实为非寻常型或可能寻常型间质性肺炎(阴性预测值 18.3%,95%CI 11.9-26.4)。
在适当的临床环境下,对于高分辨率 CT 显示可能为寻常型间质性肺炎的患者,如果由熟悉寻常型间质性肺炎模式和特发性间质性肺炎管理的区域中心的专家评估高分辨率 CT,则可能无需进行手术肺活检来确诊特发性肺纤维化。
吉利德科学公司。